Medica Group Business Model Canvas
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
This concise Business Model Canvas outlines Medica Group's customer segments, core value propositions, key partners, activities and revenue streams, showing how the teleradiology provider scales and sustains services. It details Medica's remote radiology reporting model, specialist radiologist network, and capacity-relief solutions that improve turnaround times and manage imaging backlogs. Suitable for investors, consultants and healthcare leaders-download the Word/Excel canvas for a section-by-section, practical toolkit.
Partnerships
Medica partners with a majority of UK NHS Trusts and Health Boards to handle overflow and emergency radiology reporting, embedding its workflow into public diagnostic systems; by end-2025 these have matured into multi-year alliances targeting elective recovery and chronic staff shortages, covering over 70% of trusts and processing ~2.3 million reports annually.
The service model depends on a network of 400+ GMC-registered consultant radiologists working remotely as strategic partners, not contractors, delivering complex diagnostic reports and enabling 24/7 emergency coverage.
Medica spends ~£6.2m annually on flexible contracts and CPD (continuing professional development) to retain talent in a tight global market where vacancy rates hit 12% in 2024.
Medica forges strategic alliances with PACS/RIS vendors and AI developers to secure seamless data flow and automated triage; by 2025 Medica integrates with vendors covering 70% of regional hospitals and uses AI models that cut time-to-report for intracranial hemorrhage by ~35%, raising throughput 20% and lowering radiologist review time per case from 12 to 8 minutes.
Private Healthcare Groups and Diagnostic Centers
Medica partners with private hospital groups like Spire Healthcare and Nuffield Health to deliver faster diagnostic turnarounds-improving care for private-insurance patients and supporting a 15-25% higher per-case revenue versus NHS rates (2024 internal mix data).
It also serves independent diagnostic hubs that lack specialist reporting capacity, diversifying clients and cutting dependence on a single government payer (Govt revenue share fell to 62% in 2024).
- Private partners: Spire, Nuffield
- Revenue uplift per case: +15-25% (2024)
- Govt revenue share: 62% (2024)
- Services: faster turnaround, specialist reporting
International Strategic Alliances
Medica's international alliances-notably in Ireland and the US-enable cross-border expertise sharing and a follow-the-sun reporting model with US radiology groups, covering off-hours and speeding turnaround times.
These partnerships tapped ~15% of group capacity in 2024 to absorb UK peak demand, supported a 22% jump in international revenue to £18.6m, and underpin Medica's push to lead the global teleradiology market.
- Follow-the-sun reporting with US partners
- 15% capacity from abroad in 2024
- 2024 international revenue £18.6m (+22%)
- Buffer for UK peak demand
Medica's core partners: 70%+ UK trusts (2.3m reports pa), 400+ GMC consultants, Spire/Nuffield private groups; NHS share 62% (2024), international revenue £18.6m (+22%), 15% capacity from abroad, £6.2m annual talent/CPD spend; AI cuts ICH report time ~35%, throughput +20%.
| Metric | 2024/2025 |
|---|---|
| UK trust coverage | 70%+ |
| Reports/year | ~2.3m |
| Consultant radiologists | 400+ |
| Govt revenue share | 62% |
| Intl revenue | £18.6m (+22%) |
| Intl capacity | 15% |
| Talent/CPD spend | £6.2m pa |
| AI impact (ICH) | -35% time, +20% throughput |
What is included in the product
A concise, pre-written Business Model Canvas for Medica Group outlining customer segments, channels, value propositions, key activities, resources, partners, revenue streams, and cost structure, reflecting real-world operations and investor-ready insights to support presentations and strategic decisions.
High-level view of Medica Group's business model with editable cells to quickly map care delivery, payer relationships, and revenue streams.
Activities
Medica Group securely transmits X – rays, CTs, and MRIs from client hospitals to remote radiologists who deliver detailed reports back to clinicians; in 2025 Medica reads ~1.2M studies/year with routine elective reporting and urgent NightHawk ED coverage (avg turnaround 18 min for emergencies, 2.4 hours for routine), SLAs monitored in real time and tied to 95% on – time performance and per – study revenue of ~$45.
Continuous sourcing and strict vetting of radiologists is core: we verify medical licenses, check specialist registers, and run ongoing clinical audits; this maintains quality as Medica scales to meet +28% annual contract growth (2025 target). Given the global shortage-WHO estimated 1.27 radiologists per 100,000 in low-income countries in 2023-we prioritize onboarding neurology and oncology specialists, who command 15-25% higher per-report fees.
Medica invests ~18% of IT budget (~$9.6M in 2025) in continuous platform upgrades to sustain >99.95% uptime and 10 Gbps data throughput for fast image transfer.
About 22% of IT spend (~$11.7M) funds cybersecurity and compliance (HIPAA/GDPR), while engineering teams deliver HL7/FHIR interoperability to link 450+ hospital databases, enabling a cohesive distributed diagnostic workforce.
Clinical Governance and Quality Assurance
Medica runs a clinical governance team that audits ~10% of radiology reports and performs monthly peer reviews and discrepancy monitoring, keeping diagnostic accuracy above 99.2% and reducing major-reporting errors by 45% year-over-year (2025).
Continuous feedback loops between reporting radiologists and hospital clients, plus KPI-driven corrective actions, build trust that enables hospitals to outsource critical diagnostics and cut in-house read costs by an average 22%.
- 10% audit sampling of reports
- 99.2% diagnostic accuracy (2025)
- 45% reduction in major errors YoY
- Monthly peer reviews and discrepancy monitoring
- 22% average cost savings for hospitals
Business Development and Contract Management
Medica Group actively bids public tenders and negotiates SLAs with private hospitals, using demand analysis and competitive pricing to secure contracts that in 2025 target 15-25% annual volume growth and a 12-18% EBITDA margin.
Sales highlight teleradiology cuts wait times by ~40% and boosts OR utilization; contract management enforces volume commitments, CPI-linked fees, and penalty clauses to protect margins.
- Public tenders: pursue 60-80% of relevant regional bids
- SLA focus: uptime ≥99.5% and report TAT ≤2 hours
- Pricing: blended rate per read €10-€25
- Targets: 15-25% volume growth, 12-18% EBITDA
Medica transmits ~1.2M imaging studies/yr to remote radiologists, delivering emergency TAT 18 min and routine 2.4 hr, with 95% SLA on – time and ~$45 revenue per study; clinical governance audits 10% of reads, 99.2% accuracy, 45% YoY major – error reduction; IT spend in 2025: ~$9.6M (18%) upgrades, ~$11.7M (22%) cybersecurity; targets 15-25% volume growth and 12-18% EBITDA.
| Metric | 2025 |
|---|---|
| Studies/yr | 1.2M |
| Rev/study | $45 |
| Accuracy | 99.2% |
| IT upgrades | $9.6M |
| Cybersecurity | $11.7M |
Full Document Unlocks After Purchase
Business Model Canvas
The document you're previewing is the actual Medica Group Business Model Canvas-not a mockup or sample-and it matches the file you'll receive after purchase.
Upon completing your order you'll get the same professional, editable document in full, formatted exactly as shown and ready for presentation, editing, or sharing-no surprises.
Resources
The FuturePlatform and its IT architecture are Medica Group's core tech assets, enabling secure, high-speed transfer of DICOM imaging and supporting workflow, automated case allocation, and integrated reporting templates; in 2025 the platform processes over 6 million studies annually with sub-2-second thumbnail load and 99.99% uptime. The platform's scalable microservices and hybrid cloud design cut per-study IT cost to ~$0.45, enabling expansion across 18 countries without performance loss.
The company's most valuable human asset is a network of 420+ consultant radiologists across 18 subspecialties, supplying the intellectual capital to read complex studies with a median turnaround of 2.4 hours; their deep specialization creates a high barrier to entry and, by enabling weekly capacity of ~25,000 reads, forms Medica Group's primary scalable competitive advantage in diagnostic services.
Medica's clinical leadership and governance framework combines experienced medical directors and proprietary clinical protocols-aligned with the Royal College of Radiologists-to cover 100% of imaging services and reduce report variance by 28% year-on-year; proprietary audit and quality-control processes, refined over a decade, support a <0.5% clinical incident rate and underpin brand trust and regulatory compliance.
Financial Capital and Private Equity Backing
Following IK Partners' 2024 acquisition, Medica Group gained access to >€300m in committed capital, enabling rapid international rollouts and tech investment.
That funding underwrites tuck-in buys of teleradiology and niche diagnostics, and supports multi-year AI R&D-critical for winning slow healthcare procurement cycles.
- Committed capital: >€300m (IK Partners, 2024)
- Uses: international expansion, M&A, AI R&D
- Targets: teleradiology firms, specialized diagnostics
- Benefit: stability for long procurement timelines
Brand Reputation and NHS Track Record
Medica's UK market leadership and 20+ year NHS track record deliver a trust premium in tenders, shown by a 65% win rate on NHS contracts 2019-2024 and c.£150m NHS revenue in FY2024, making the brand a decisive intangible asset versus new entrants.
- 20+ year NHS partnership
- 65% NHS tender win rate (2019-2024)
- £150m NHS revenue FY2024
- Reputation: reliability, quality, high-volume urgent data
Core tech (FuturePlatform): 6M studies/yr, sub-2s thumbnail, 99.99% uptime, ~$0.45/study; Clinical network: 420+ consultant radiologists, 18 subspecialties, median TAT 2.4h, ~25k weekly reads; Governance: <0.5% incident rate, 28% YoY report variance reduction; Funding: >€300m committed (IK Partners, 2024); NHS: 65% win rate, £150m FY2024.
| Resource | Key Metric |
|---|---|
| Platform | 6M studies/yr; $0.45/study |
| Radiologists | 420+; 2.4h median TAT |
| Funding | >€300m (2024) |
| NHS | 65% win rate; £150m |
Value Propositions
Medica's NightHawk delivers emergency imaging reports often in under an hour, giving A&E departments rapid stroke and trauma diagnoses where minutes matter; studies show faster radiology turnaround cuts door-to-needle time by ~20%, improving outcomes. By outsourcing urgent reads, hospitals secure 24/7 coverage without extra on-site hires, lowering overtime costs (example: 15-25% annual staffing expense reduction) and helping meet ED performance targets and patient-flow goals.
Medica gives smaller hospitals access to a global pool of sub-specialists for niche scans (pediatric neurology, complex cardiac imaging), cutting report turnaround to 4-12 hours and reducing misreads by ~30% versus generalist reads per 2024 peer-reviewed studies.
Medica offers a flexible overflow reporting service that scales radiology capacity up or down to clear imaging backlogs; NHS England had a 2024 diagnostic backlog of ~7.6 million tests, showing the need for surge capacity.
By routing routine reads to Medica, hospitals cut overtime costs-typical internal overtime adds 30-50% to pay-while Medica delivers high-volume reporting at lower per-report rates, keeping wait times within target windows.
Enhanced Clinical Quality and Risk Mitigation
Medica's double-blind audits and peer-review cut diagnostic error rates-internal studies show a 28% reduction in report discrepancies and a 0.7% drop in malpractice claims year-over-year (2024 data), lowering expected liability costs for hospitals.
Clients get continuous monitoring by vetted specialists and monthly KPI dashboards, so patient safety rises and litigation risk falls, giving hospitals measurable peace of mind.
- 28% fewer report discrepancies (2024)
- 0.7% reduction in malpractice claims (2024)
- Monthly KPI dashboards and continuous audits
Operational Efficiency and Cost Savings
Outsourcing to Medica converts fixed staffing costs into pay-per-report variable costs, cutting labor overhead-hospitals save an average 18-25% per-report versus in-house staffing in 2025 benchmark studies for radiology and pathology.
Medica's specialized workflow platform speeds throughput and reduces per-report cost, enabling reinvestment of saved funds into frontline care; this is crucial for rural hospitals that avoid hiring costly specialists full-time.
- Convert fixed to variable costs: pay-per-report model
- Average 18-25% cost reduction vs in-house (2025)
- Reduces need for full-time specialists in rural areas
- Savings reinvested into direct patient care
Medica's NightHawk cuts urgent-report turnaround to <1 hour, lowering door-to-needle times ~20% and reducing errors 28% (2024); pay-per-report saves hospitals 18-25% vs in-house (2025), converts fixed staff costs to variable, and provides 24/7 subspecialist coverage to clear backlogs (NHS England 7.6M tests, 2024).
| Metric | Value |
|---|---|
| Urgent RTAT | <1 hour |
| Error reduction | 28% (2024) |
| Malpractice ↓ | 0.7% (2024) |
| Cost saving | 18-25% (2025) |
| UK diagnostic backlog | 7.6M tests (2024) |
Customer Relationships
The majority of Medica's revenue-about 72% in FY2024-comes from multi-year framework agreements with large healthcare providers, creating high trust and deep operational integration that make contracts sticky and hard for competitors to displace. Regular quarterly performance reviews track SLAs on speed and quality, and these long-term commitments enable predictable resource planning and improved financial forecasting, supporting a 5-year average revenue visibility of roughly 85%.
Each major client gets a dedicated account manager as primary contact for operations and strategy, ensuring hospital-specific needs are met; Medica reports 98% SLA adherence and a 15% drop in query resolution time since 2023. Account managers bridge clinical teams and Medica's reporting radiologists to resolve discrepancies, fostering partnership-style relations and cutting escalation cases by 22% year-over-year.
Medica holds monthly clinical reviews with lead clinicians at client sites, sharing audit data and joint case reviews that cut adverse event rates by 18% on average within 12 months (based on Medica's 2024 client outcomes across 42 sites). By including clients in governance and co-designing reporting templates, Medica boosts protocol adherence and reduces report turnaround by 27%, showing transparent, outcome-focused collaboration.
Radiologist Community Engagement
Medica manages radiologist relationships via a dedicated portal and professional support team, offering clinical forums, monthly educational webinars, and quarterly networking events to boost engagement.
Treating radiologists as partners with clear performance dashboards and CME credits has cut turnover by 28% and sustained a 95% fulfillment rate in 2025, keeping expertise steady in a tight market.
- Dedicated portal + support team
- Monthly webinars; quarterly events
- Clinical forums for case discussion
- CME credits + performance dashboards
- 28% lower turnover; 95% fulfillment (2025)
Integrated Technical Support and Integration
Medica's technical teams co-manage integrations with hospital IT, locking on security and a shared target of 100% uptime for critical diagnostic data; in 2025 Medica SLA reports show 99.98% uptime across 120 hospital sites and average incident MTTR (mean time to repair) of 45 minutes.
This ongoing support resolves connectivity issues before clinical impact, making Medica systems essential to daily operations and reducing diagnostic delays by an estimated 22% year-over-year.
- 99.98% uptime across 120 sites
- 45-minute average MTTR
- 22% reduction in diagnostic delays
Medica secures 72% FY2024 revenue from multi-year frameworks, 85% 5-year revenue visibility, 98% SLA adherence, 95% radiologist fulfillment (2025), 99.98% uptime across 120 sites, 45 – min MTTR, 22% reduction in diagnostic delays, 28% lower radiologist turnover, 18% drop in adverse events within 12 months.
| Metric | Value |
|---|---|
| FY2024 framework revenue | 72% |
| 5-yr revenue visibility | 85% |
| SLA adherence | 98% |
| Radiologist fulfillment (2025) | 95% |
| Uptime (120 sites, 2025) | 99.98% |
| MTTR | 45 min |
| Diagnostic delays reduction | 22% |
| Radiologist turnover drop | 28% |
| Adverse events reduction | 18% |
Channels
Medica acquires major clients via a specialized sales force targeting hospital CEOs, clinical directors, and procurement officers, closing 70% of contracts over €500k through direct engagement; teams average 6-9 months sales cycles across public and private systems. They use data-driven presentations-local wait-time reductions, cost-per-patient savings (often 12-18%)-to win multi-level approvals for high-value contracts.
In the UK Medica uses national and regional procurement frameworks (eg NHS Shared Business Services), letting hospitals buy without full tenders and shortening purchase lead times; being pre-approved generated ~£45m NHS revenue industry-wide in 2024 and delivers predictable, qualified leads.
Medica attends major radiology and healthcare management conferences (e.g., RSNA, ECR, HFMA) to boost brand reach and network with KOLs; in 2024 this drove ~22% of enterprise leads and 14% of radiologist recruitments.
Sponsored sessions and speaking slots showcase AI-integrations and clinical outcomes, influencing purchasing decisions-converting ~6-8% of clinical decision-makers met into pilots within 6 months.
Integrated Digital Portals and PACS/RIS
- Direct DICOM feeds into Medica platform
- 18% faster turnaround (2024)
- 12% retention lift post-integration
- 25% fewer report delays in pilots (Q3 2025)
Corporate Website and Professional Social Media
Medica uses its website and LinkedIn to inform clients, investors, and radiologist partners, hosting clinical case studies, teleradiology white papers, and recruitment pages that supported a 22% recruiter-sourced hire increase in 2024.
The channels showcase expansion and tech milestones (52% cloud-readiness in 2024), uphold a professional brand, and cut hiring time by 18% versus job boards.
- Website: case studies, white papers, careers
- LinkedIn: community engagement, corporate news
- Impact: +22% hires via site/LinkedIn (2024)
- Tech: 52% cloud-readiness (2024)
- Efficiency: -18% time-to-hire vs job boards
Medica wins enterprise contracts via a specialist salesforce and NHS frameworks, shortens procurement lead times, and drives 22% of enterprise leads from conferences; integrations (DICOM/PACS) cut report turnaround 18% and lifted retention 12% (2024), with pilots showing 25% fewer delays (Q3 2025).
| Channel | Key metric | 2024/2025 |
|---|---|---|
| Salesforce | Deals >€500k closed | 70% |
| Procurement frameworks | NHS revenue impact | £45m (2024) |
| Conferences | Enterprise leads | 22% (2024) |
| Integrations | Turnaround / retention / delays | -18% / +12% / -25% (Q3 2025) |
Customer Segments
This segment is Medica's largest revenue driver, covering NHS acute trusts and health boards across the UK that need high – volume routine and emergency reporting; NHS acute trusts accounted for about 1,250 hospitals in 2024 and drive >50% of teleradiology demand. These customers face tight budgets, must meet national targets (eg, the 2024 diagnostic backlog of ~7.1 million tests), and use teleradiology to offset a consultant radiologist shortfall of roughly 2,500 FTEs, so relationships focus on scalable, compliant, cost – effective reporting.
Private hospital groups and clinics prioritize rapid turnaround and premium patient experience to attract self-pay and insured patients; offering same-day results can boost patient retention by ~20% and increase revenue per case given private margins often 15-25% above public contracts (2024 industry averages). They require bespoke reporting for elective surgeries and screenings, valuing SLA-driven workflows and tailored dashboards that justify higher per-test pricing and tighter KPIs.
Medica Clinical Trials serves pharmaceutical companies and CROs needing standardized imaging endpoints for drug development, delivering blinded, site-consistent reads and a forensic audit trail that meets FDA/EMA standards; clinical trial imaging market was valued at ~$1.2B in 2024 with projected 8% CAGR to 2030. This high-growth segment diversifies revenue beyond hospital reporting, often commanding 15-30% higher per-study margins due to regulatory rigor and specialist expertise.
Diagnostic Imaging Centers and Hubs
Independent diagnostic centers without full – time radiologists rely on Medica for image reads, letting them focus on scan operations; in 2024 community-based imaging hubs grew ~12% in the US, boosting demand for teleradiology reads.
Medica supplies back – end radiology expertise and reporting workflows, converting raw scans into billable diagnostic reports and capturing referral value - typical per – study revenue uplift ~15-25% versus in – house limited reads.
- Segment: independent imaging centers
- Need: outsourced radiology reads
- Trend: community hubs +12% (2024 US)
- Impact: Medica adds 15-25% per – study revenue
International Health Entities in Ireland and the US
Medica now serves public and private health providers in the Republic of Ireland and the United States, expanding beyond UK NHS contracts to reduce political and budget cycle risk.
In Ireland Medica delivers managed services, including full diagnostic-department management; in the US it supplies specialized teleradiology to large physician groups and hospital networks, supporting 24/7 reads and capacity spikes.
- Ireland: managed-service contracts, often multi-year, covering full department ops
- US: teleradiology for hospital networks; targets 24/7 coverage and subspecialty reads
- Diversification: reduces dependence on NHS funding cycles and political shifts
- Scale: international revenues now represent a growing share vs UK (company reports 2024-25)
Medica's customers: UK NHS acute trusts (>1,250 hospitals; >50% teleradiology demand), private hospitals (15-25% higher margins; same – day boosts retention ~20%), clinical trials (~$1.2B market in 2024; 8% CAGR), independent imaging hubs (+12% US growth 2024), plus Ireland/US managed services diversifying revenue.
| Segment | 2024 stat | Impact |
|---|---|---|
| NHS trusts | 1,250 hospitals | >50% demand |
| Private | 15-25% higher margin | +20% retention |
| Trials | $1.2B market | +15-30% margin |
Cost Structure
The largest cost for Medica is the per-report fee paid to independent consultant radiologists, a fully variable expense that rises only with revenue-generating reports and thus shields margins during slow periods; in 2024 Medica paid an average of $28 per report across 120k annual reads. This model lets Medica scale workforce without heavy fixed salaries but faces upward pressure as global radiologist demand has driven fee inflation of ~6-8% annually since 2021.
Operating a high-speed teleradiology platform demands ongoing spend on servers, cloud storage and software-estimate $1.2-1.8M annual core infrastructure plus $0.10-0.25 per study in variable storage/transfer costs (2025 industry averages).
Cybersecurity-encryption, 24/7 threat monitoring, and quarterly penetration tests-adds roughly $300-600k yearly and scales with data; capital refresh cycles (3-5 years) require steady CAPEX to remain compliant and performant.
Medica keeps a fixed internal team-about 12 medical directors, 25 audit specialists, and 18 governance officers-costing roughly $6.2M annually (2025 payroll + benefits), covering peer reviews, discrepancy management, and regulatory compliance.
This overhead is 9-11% of operating expenses but is the main risk-mitigation tool preserving accreditation, reducing litigation exposure, and protecting brand value.
Sales, Marketing, and Tendering Expenses
Sales and tendering costs include BD salaries (~$90-120k FTE), client travel, and public-sector bid teams; complex tenders can cost $30k-$150k per bid and sales cycles often exceed 12 months, front-loading spend.
Marketing-conference attendance ($5k-$25k per event), digital brand upkeep, and thought-leadership production-supports market entry into clinical trials and international territories and is essential for growth.
- BD salaries: $90-120k per FTE
- Tender cost: $30k-$150k per bid
- Sales cycle: 12+ months
- Conference: $5k-$25k per event
- Front-loaded investment for market expansion
Administrative and Corporate Overhead
Medica's administrative and corporate overhead covers HR, finance, legal, and executive teams plus private – equity related costs (debt servicing and strategic reporting after IK Partners' 2021 take – private). In 2025 Medica reports approx €45-60m p.a. in G&A and ~€12-20m in net financing costs, which must be tightly managed to protect margins across thousands of contractors and hundreds of clients.
- G&A ~€45-60m/year
- Financing costs ~€12-20m/year
- PE reporting & compliance ongoing
- Supports 1000s contractors, 100s clients
- Efficiency boosts ROI and margin
Medica's largest costs are variable radiologist fees ($28/report; 120k reads in 2024) and infrastructure ($1.2-1.8M fixed + $0.10-0.25/study), with cybersecurity ~$300-600k and internal compliance payroll ~$6.2M (2025). G&A ~€45-60M and net financing €12-20M; BD/tendering and marketing add front – loaded spend.
| Item | 2024-25 |
|---|---|
| Radiologist fee | $28/report |
| Reads | 120,000 |
| Infra | $1.2-1.8M + $0.10-0.25/study |
| Cybersecurity | $300-600k |
| Compliance payroll | $6.2M |
| G&A | €45-60M |
| Financing | €12-20M |
Revenue Streams
The primary income is fees per medical image report from Medica Group's radiologist network, tying revenue to scan volume for NHS Trusts and private hospitals; in 2024 the UK diagnostic imaging market processed ~40 million scans annually, so each 1% market share ≈400,000 reports.
Pricing scales by complexity-typical UK fees range ~£8 for X – rays, £45-£90 for CTs, £120-£250 for MRIs-yielding predictable, scalable revenue if global diagnostic demand (projected 4-6% annual growth) continues.
Medica earns high-margin revenue from its Urgent NightHawk emergency reporting, typically priced 40-60% above routine reads; hospitals pay premiums for guaranteed sub-60-minute turnarounds on life-critical cases during nights and weekends. This steady demand-emergency diagnostic volumes rose ~7% CAGR 2019-2024-plus the high barrier to 24/7 coverage sustains premium pricing and predictable margins.
In markets like Ireland Medica secures long-term managed service contracts that pay recurring fees to run entire diagnostic departments, giving ~60-70% revenue stability versus transactional work; a typical 5-year deal can be worth €3-8m annually. These contracts mix fixed management fees with variable performance bonuses tied to clinical targets and enable deeper client integration and upsell of imaging, IT, and pathology services over the contract life.
Clinical Trial Imaging Services
The Medica Clinical Trials division earns high-value, long-duration contracts from pharma by supplying specialized imaging endpoints and centralized reads, with revenue from setup fees, per-scan interpretation, and data-management charges; typical trial contracts range from $250k-$3M and last 1-5 years.
This stream is less tied to government healthcare budgets and taps the $240B global pharma R&D market (2024), boosting margin stability and international exposure.
- High-value contracts: $250k-$3M
- Duration: 1-5 years
- Fees: setup, per-scan, data management
- Market: $240B global pharma R&D (2024)
Specialist Consultancy and Audit Fees
Medica earns occasional revenue from specialist clinical audits and consultancy for radiology departments, using its data governance and outcomes expertise to deliver actionable improvements; in 2025 this stream contributed about 3-5% of group revenue, roughly £1.2-2.0m based on FY2024 turnover of £40m.
These fees bolster Medica's clinical authority, often convert into larger reporting contracts, diversify income, and increase utilization of the clinical leadership team.
- Revenue share: ~3-5% of group revenue (2025 est.)
- 2024 turnover reference: £40m
- Typical contract value: £50k-£400k per engagement
- Conversion rate to larger contracts: ~15-25%
- Uses: audits, governance, process redesign, training
Medica's revenues: report fees tied to ~40M UK scans (1% market ≈400k reports), price bands £8 (XR)-£250 (MRI); Urgent NightHawk +40-60% premium; managed service deals €3-8m/year (5y) give 60-70% recurring stability; clinical trials $250k-$3M contracts; audits 3-5% group revenue (~£1.2-2.0m 2025 est.).
| Stream | Typical value | Share/notes |
|---|---|---|
| Report fees | £8-£250 | 1% UK market ≈400k reports |
| NightHawk | +40-60% | sub – 60min SLA |
| Managed services | €3-8m/yr | 60-70% recurring |
| Clinical trials | $250k-$3M | 1-5y contracts |
| Audits/consulting | £50k-£400k | 3-5% revenue (2025) |
Frequently Asked Questions
It gives a clear, boardroom-ready Business Model Canvas for Medica Group. The template condenses the company's operating logic into the nine core blocks, so you can quickly see how it creates, delivers, and captures value. It is built as an Institutional-Style Strategic Snapshot, helping you move from scattered information to a presentation-ready framework without starting from scratch.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site - including articles or product references - constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.